Tracking tidal volume noninvasively in volunteers using a tightly controlled temperature-based device: A proof of concept paper.

INTRODUCTION: There is a paucity of noninvasive respiratory monitors for patients outside of critical care settings. The Linshom respiratory monitoring device is a novel temperature-based respiratory monitor that measures the respiratory rate as accurately as capnography. OBJECTIVES: Determine whether the amplitude of the Linshom temperature profile was an accurate, surrogate and qualitative metric of the tidal volume (VT ) that tracks VT in healthy volunteers. METHODS: Forty volunteers breathed room air spontaneously through a tight-fitting continuous positive airway pressure mask with a Linshom device mounted in the mask. VT was measured contemporaneously using a standalone Maquet Servo-i ICU ventilator. The amplitudes of the Linshom temperature profiles were paired with the contemporaneous VT measurements using least squares linear regression analysis and the coefficient of variation (R2 ) was determined. RESULTS: Forty volunteers completed the study. The data from 30 of the volunteers were analysed and are presented; data from 10 volunteers were not included due to protocol violations and/or technical issues unrelated to Linshom. The fluctuations in the amplitude of the Linshom temperature profiles mapped closely with the measured VT using least squares linear regression analyses yielding a mean R2 (95% CI) value of 0.87 (0.84-0.90). CONCLUSION: These results support the notion that the Linshom temperature profile is an accurate and reliable surrogate that tracks changes in VT in healthy volunteers. Further studies are warranted in patients in clinical settings to establish the effectiveness of this monitor.

An update on the safety of prescribing opioids in pediatrics.

INTRODUCTION: The opioid abuse epidemic and its toll on the adolescent population have heightened awareness for safer opioid prescribing practices in pediatric pain management. Opioids remain the mainstay of therapy for severe pain, although there is an emphasis on multimodal therapy. Areas covered: In this update, the authors present information on parenteral/oral opioids commonly used in pediatrics. Recommendations for opioid use in special circumstances including neonates and developmental pharmacokinetic concerns are discussed. Due to noticeable interindividual variability, pharmacogenomics may be important for tailoring pain regimens. In particular, the role of CYP2D6 phenotypes on opioid selection/dosing and clinical implications are discussed. A summary of adverse effects and opioid safety data, and the role of regulations, risk assessment, Centers for Disease Control and Prevention guidelines, follow-up, and monitoring for compliance in opioid prescribing, are detailed. Expert opinion: 'One size does not fit all' describes the need for public policies focused on pediatric pain and opioid use, as children are not 'little adults.' Clinical trials to evaluate pharmacokinetics-pharmacodynamics of opioids are currently lacking. Development of novel biased opioid agonists, clinical integration of genetics in informed decision-making, and emphasis on top-down approaches to pain management will be key to decrease opioid reliance.